[A quinapril-hydrochlorothiazide combination in the treatment of essential arterial hypertension]. / L'associazione quinapril/idroclorotiazide nel trattamento dell'ipertensione arteriosa essenziale.

This open, non-controlled study was planned to investigate efficacy and tolerability of fixed combination quinapril 20 mg plus hydrochlorothiazide 12.5 mg for treatment of mild-to-moderate essential hypertension. One hundred and fifty seven patients, with diastolic pressure ranging 105-119 mmHg, were enrolled after two weeks wash-out; during this period patients received placebo. After placebo phase, patients received one tablet/day of fixed combination for six weeks: at the end of this period patients were classified as "responder" (lowering of pressure = or > 10 mmHg) or "non responder"; "non responder" were planned to receive two tablets/day while "responder" maintained the former posology. Patients were reexamined after four weeks: "non responder" were dropped out while "responder" maintained the actual posology. Study was performed in fourteen weeks totally; at the end of this period fourteen patients were classified as "non responder". The fixed combination quinapril 20 mg plus hydrochlorothiazide 12.5 mg can be considered a valid drug for the treatment of mild-to-moderate hypertension.

[Epidemiology and treatment of long-term male impotence]. / Epidemiologia e trattamento long-term dell'impotenza sessuale maschile.

Male impotence has assumed increasing clinical importance and the perfection of diagnostic and therapeutic methods has opened new horizons for medical treatment. The aim of this paper is to provide a review of the epidemiology of this disorder with the relative diagnostic and therapeutic correlations. The authors report a series of 161 patients who were treated for one year at most with prostaglandin E1 (Alprostadil alpha-cyclodextrin).

[Interaction of diazepam and levodropropizine evaluated with quantitative EEG]. / Intéraction entre la diazépam et la lévodropropizine évaluée par la quantification de l'EEG.

The purpose of this clinical trial was to evaluate the presence of possible interactions between Levodropropizine and benzodiazepines (BZ). Experience was performed recording bioccipital quantified EEG in 5 healthy volunteers in normal conditions, after BZ administration and after BZ plus Levodropropizine administration. The slight shifting towards lower frequences in quantified EEG, due to BZ, was not modified by Levodropropizine administration. As results from this experience Levodropropizine seems not to have sinergic action on BZ effect in quantified EEG.

Ciprofloxacin: multiple-dose pharmacokinetic and clinical results in patients with hypercrinic bronchopulmonary diseases.

Ciprofloxacin, a 4-quinolone derivative with a wider spectrum of activity as compared to classic quinolones employed in the therapy of urinary tract infections, was studied in view of its possible application in the therapy of bronchopulmonary infections. An oral dose of 500 mg every 12 h was administered and both the clinical response and the pharmacokinetic profile were investigated. A complete recovery was reached in 87.5% of patients and an improvement in 12.5%; no failure was recorded. A very good penetration in sputum was confirmed by the sputum/serum area under curve ratio, providing evidence for a high bioavailability in bronchial secretion. Lung tissue concentrations confirmed the good peripheral distribution of ciprofloxacin. A twelve-hour administration schedule allows high peripheral concentrations to be obtained superior or equal to the minimum inhibitory concentrations for many pathogens.